Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.

The live and archived webcast will be accessible from the Company's website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 60 days.

The Ghana Health Service (GHS) has called for local resource mobilization and empowerment of indigenous pharmaceutical ...

Biomarin Pharmaceutical Inc (BMRN) stock saw a modest uptick, ending the day at $61.8 which represents a slight increase of $0.07 or 0.11% from the prior close of $61.73. The stock opened at $62.1 and ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

The Nifty Pharma index fell nearly 3% in intraday trade on January 28, marking its third consecutive session of decline, with ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

The company will report earnings before the open on Jan. 29 Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

Pharmaceutical companies have already raised the price of over 800 brand-name prescription drugs this year. Nearly all the ...